|
another site by net advantage
|
| |
| Company
Profile |
Diagnostic
Potentials Ltd is developing a range of diagnostic and monitoring
systems for Central Nervous system (CNS) disease states. The
first product that has been developed is a system for the early
diagnosis of Alzheimer's Disease that will enable clinical consultants
to make a positive decision on the care of the patient and on
the prescribing of drugs.
CNS disorders, such as Alzheimer's, Parkinson's, schizophrenia,
and others, represent more than 15% of the global cost for disease.
For example, costs of over $100 billion per annum makes Alzheimer's
the third most expensive disease in the USA.
Advances in drug treatments are creating opportunities to reduce
the suffering and cost associated with CNS disorders. The key
to exploiting these opportunities, both for clinical care providers
and for drug companies, is early and accurate diagnosis.
The unmet need in this market is an "industry standard"
diagnostic tool. Diagnostic Potentials has developed a platform
technology which meets the needs of both clinical and pharmaceutical
customers for early and accurate assessment of CNS disorders.
|
| Pipeline |
The
diagnostic tool for Alzheimer's disease represents the first
of a series of planned CNS assessment tools. The company plans
to initiate development of tools for assessing Parkinson's disease
and schizophrenia in early 2002.
|
| History |
| Diagnostic
Potentials is a spin-out company from the Department of Psychology,
University of Glasgow. The company commenced operations in July
1999 and began its development program in October that year.
After achieving outstanding success with the research and development
phase in the early part of 2000, the system was tested on a
suitable number of subjects in the second half of that year
reaching proof of concept in December. |
 |
|
